SCHEMBL6547642

SCHEMBL6547642

Nc1ccc(CCC(C(=O)O)N2CCN(CC(=O)O)CCN(CC(=O)O)CCN(CC(=O)O)CC2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALB P02768 1/20 0.48
SLC6A9 P48067 1/20 0.43
S1PR1 P21453 1/20 0.41
SIGMAR1 Q99720 1/20 0.39
SLC6A3 Q01959 1/20 0.39
TACR1 P25103 1/20 0.36
FOLH1 Q04609 1/20 0.36
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
ALDH1A1 P00352 2/20 0.36
MAPT P10636 1/20 0.36
HTT P42858 1/20 0.36
LMNA P02545 1/20 0.35
KDM4E B2RXH2 1/20 0.35
CACNA2D1 P54289 1/20 0.35
CACNA1B Q00975 1/20 0.35
CACNB1 Q02641 1/20 0.35
CACNA1C Q13936 1/20 0.35
POLB P06746 1/20 0.35
ACE P12821 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8656680 0.93 ALB (0.44) ALBSLC6A9S1PR1SIGMAR1SLC6A3
SCHEMBL883651 0.91 ALB (0.42) ALBSLC6A9S1PR1SIGMAR1SLC6A3
SCHEMBL10305290 0.90 ALB (0.42) ALBSLC6A9S1PR1FOLH1
SCHEMBL4368905 0.87 ALB (0.40) ALBSLC6A9S1PR1SIGMAR1SLC6A3
SCHEMBL9877605 0.86 LMNA (0.49) ALBSLC6A9S1PR1SLC6A3TACR1
SCHEMBL4366090 0.85 ALB (0.39) ALBSLC6A9S1PR1SIGMAR1TACR1
SCHEMBL24507414 0.84 MMP12 (0.47) ALBSLC6A9S1PR1SIGMAR1SLC6A3
SCHEMBL17986179 0.83 KCNJ1 (0.50) ALBSIGMAR1SLC6A3KDM4EPOLB
SCHEMBL8657520 0.83 KCNJ1 (0.50) ALBSIGMAR1SLC6A3KDM4EPOLB
SCHEMBL16922663 0.81 ALB (0.44) ALBSLC6A9S1PR1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025122615-A1 ENRICHED AND STABLE RADIOLIGAND THERAPY FORMULATIONS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME MARIANA ONCOLOGY INC. (US) 2025-06-12 WO claimed
US-20240352199-A1 METHOD FOR PREPARATION OF FIXED SWELLABLE POLYMER PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION (KR) 2024-10-24 US claimed
EP-4408484-A1 MULTIFUNCTIONAL COMPOUNDS FOR USE IN MEDICAL IMAGING AND THERAPY Antelope Surgical Solutions, Inc. (US) 2024-08-07 EP claimed
CN-118338916-A Multifunctional compounds for use in medical imaging and therapy 安特络手术解决方案公司 2024-07-12 CN claimed
EP-4389804-A1 METHOD FOR PREPARING SWELLABLE POLYMER TO WHICH OBJECT IS FIXED Pusan National University Industry-University Cooperation Foundation (KR) 2024-06-26 EP claimed
CN-118019782-A Method for producing object-immobilized swellable polymer 釜山大学校产学协力团 2024-05-10 CN claimed
CN-116970033-A Enzymatic self-assembled molecular probe, preparation method and application thereof 江苏省原子医学研究所 2023-10-31 CN claimed
US-20230256122-A1 COMBINATION THERAPY FOR TREATING CANCER CITY OF HOPE 2023-08-17 US claimed
US-20230149569-A1 MULTIFUNCTIONAL COMPOUNDS FOR USE IN MEDICAL IMAGING AND THERAPY ANTELOPE SURGICAL SOLUTIONS, INC. 2023-05-18 US claimed
WO-2023056221-A1 MULTIFUNCTIONAL COMPOUNDS FOR USE IN MEDICAL IMAGING AND THERAPY ANTELOPE SURGICAL SOLUTIONS, INC. (US) 2023-04-06 WO claimed
US-5652361-A ANTITUMOR THE DOW CHEMICAL COMPANY (US) 1997-07-29 US claimed
EP-0662842-A1 PROCESS FOR PREPARING MACROCYCLIC CHELATING AGENTS AND FORMATION OF CHELATES AND CONJUGATES THEREOF THE DOW CHEMICAL COMPANY (US) 1995-07-19 EP claimed
EP-0353450-B1 Macrocyclic bifunctional chelants, complexes thereof and their antibody conjugates DOW CHEMICAL CO (US) 1995-03-29 EP claimed
WO-1993020852-A2 MACROCYCLIC CHELATING AGENTS, CHELATES AND CONJUGATES THEREOF THE DOW CHEMICAL COMPANY (US) 1993-10-28 WO claimed
US-5133956-A Radiolabeled metal-binding protein for the treatment of arthritis THE DOW CHEMICAL COMPANY (US) 1992-07-28 US claimed
EP-0420942-A1 MACROCYCLIC BIFUNCTIONAL CHELANTS, COMPLEXES THEREOF AND THEIR ANTIBODY CONJUGATES THE DOW CHEMICAL COMPANY (US) 1991-04-10 EP claimed
WO-1990007342-A1 PROCESS FOR PREPARING ISOTHIOCYANATO FUNCTIONALIZED METAL COMPLEXES THE DOW CHEMICAL COMPANY (US) 1990-07-12 WO claimed
EP-0374947-A1 Process for preparing isothiocyanato functionalized metal complexes THE DOW CHEMICAL COMPANY (US) 1990-06-27 EP claimed
EP-0353450-A1 Macrocyclic bifunctional chelants, complexes thereof and their antibody conjugates THE DOW CHEMICAL COMPANY (US) 1990-02-07 EP claimed
WO-1989012631-A1 MACROCYCLIC BIFUNCTIONAL CHELANTS, COMPLEXES THEREOF AND THEIR ANTIBODY CONJUGATES THE DOW CHEMICAL COMPANY (US) 1989-12-28 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230149569-A1 MULTIFUNCTIONAL COMPOUNDS FOR USE IN MEDICAL IMAGING AND THERAPY PAICS, BID, OGFR ALB 104/4885SLC6A9 4116/4885S1PR1 473/4885
US-20230256122-A1 COMBINATION THERAPY FOR TREATING CANCER IL2, IL2RA, IL15 ALB 138/4885SLC6A9 4133/4885S1PR1 1214/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.